Federated Wireless Powers First Fully Private 5G Network Authorized to Operate Within the Department of War 
Asia Pioneer Entertainment Signs Strategic Agreement with Global Playing Card Brand BEE(R) in Macau 
AEON Credit Records 16.9% Net Profit Growth in FY2025/26 SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace CARSON…
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace CARSON…
Aspargo Extends Latin America Reach From Mexico to Argentina
Disrupting Erectile Dysfunction (ED) Market With Oral Spray Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’…
Aspargo Extends Latin America Reach From Mexico to Argentina
Disrupting Erectile Dysfunction (ED) Market With Oral Spray Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’…
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
Data was included in scientific programming at the annual meeting of The Retina Society ATLANTA,…
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
Data was included in scientific programming at the annual meeting of The Retina Society ATLANTA,…
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid…
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid…
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in…
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in…
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
Influid Water-soluble Nanotechnology Avicanna’s Patent-Pending Influid Technology Inside Viola Water-Soluble THC Infuser Developed through Avicanna’s…
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
Influid Water-soluble Nanotechnology Avicanna’s Patent-Pending Influid Technology Inside Viola Water-Soluble THC Infuser Developed through Avicanna’s…
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent…
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent…
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…